PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 29, 2026Journal of the American Pharmacists Association0 citationsOpen Access

Overview of clinical trials on deprescribing: A comprehensive analysis of the ClinicalTrials.gov database

View Full Paper
YWYu WangYGYingying GongXZXiangbin Zhong

Key Points

  • This study aims to provide a comprehensive overview of deprescribing trials registered in ClinicalTrials.gov.
  • Searched ClinicalTrials.gov for deprescribing trials and analyzed their characteristics.
  • Confirmed publication statuses of primary completed trials using PubMed and Google Scholar.
  • Identified 125 deprescribing trials; only 39.2% were completed.
  • 88.0% were interventional, with 56.0% enrolling only the elderly and 70.4% being single-center trials.
  • The cumulative publication rate within five years of completion was 60.7%.

Abstract

AbstractBackground Understanding the current features of deprescribing clinical trials is crucial for improving trial designs and identifying research gaps. Objective This study aims to provide a comprehensive overview of deprescribing trials registered in ClinicalTrials.gov. Methods We searched the ClinicalTrials.gov database for deprescribing clinical trials and evaluated the characteristics of these relevant studies. For the primary completed trials, we also searched PubMed and Google Scholar to confirm their publication statuses. Results We identified 125 deprescribing trials for analysis. Only 39.2% were completed, 88.0% were interventional trials, 56.0% enrolled only the elderly, 70.4% were single-center clinical trials, and 35.2% were sited in the United States. The number of interventional trials registered before patient recruitment from 2021 to 2025 was higher than that from 2012 to 2020 (P P Conclusion Our study showed that deprescribing trials are mostly large-scale and single-center studies, mainly carried out in developed countries, and most of them are incomplete, lacking results and publications. Therefore, it is necessary to carry out such trials in developing countries, and to pay more attention to improving their completion rates, as well as promoting the publication and dissemination of their results.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a192cf8fab5b468c4415bd3https://doi.org/10.1016/j.japh.2026.103150
Ask AI
Helpful
Bookmark
Share
View Full Paper